ArticleFrontiers in immunology2021
Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 95 citations in OpenAlex.
- LLPS-based classification and a novel prognostic signature reveal NRF1 as a therapeutic target in pancreatic cancer.Cancer cell international · 2026Article
- Integrated bioinformatics and immunohistochemical analysis reveal that S100A16 is correlated with mutational burden, immune evasion, andInternational journal of clinical and experimental pathology · 2026Article
- Bioinformatics-based screening and prediction of compounds and antigen epitopes for immune targets with point mutations in colitis-associated colorectal cancer.Discover oncology · 2025Article
- The role of RAB GTPases in predicting prognosis and therapy response in pancreatic cancer.Discover oncology · 2025Article
- Hypoxia- and lactate metabolism-associated prognostic and therapeutic signature in pancreatic cancer.Discover oncology · 2025Article
- Construction and evaluation of a prognostic model of autophagy-related genes in hepatocellular carcinoma.Biochemistry and biophysics reports · 2025Article
- T cell receptor signaling pathway subgroups and construction of a novel prognostic model in osteosarcoma.Heliyon · 2025Article
- Integrative multi-omics analysis reveals the role of toll-like receptor signaling in pancreatic cancer.Scientific reports · 2025Article
- An immune-related signature based on molecular subtypes for predicting the prognosis and immunotherapy efficacy of hepatocellular carcinoma.Frontiers in immunology · 2025Article
- Integrative Analysis of eQTL Genes Reveals Key Biomarkers and Mechanisms for Early Diagnosis of Pancreatic Ductal Adenocarcinoma.Cancer informatics · 2025Article
- Prognostic and immunotherapeutic potential of disulfidptosis-associated signature in pancreatic cancer.Frontiers in immunology · 2025Article
- A hypoxia-derived gene signature to suggest cisplatin-based therapeutic responses in patients with cervical cancer.Computational and structural biotechnology journal · 2024Article
- Hypoxia-related bioinformatic signatures associated with prognosis and tumor microenvironment of pancreatic cancer: Current status, concerns, and future perspectives.World journal of gastroenterology · 2024Article
- Establishment and Verification of a Novel Gene Signature Connecting Hypoxia and Lactylation for Predicting Prognosis and Immunotherapy of Pancreatic Ductal Adenocarcinoma Patients by Integrating Multi-Machine Learning and Single-Cell Analysis.International journal of molecular sciences · 2024Article
- The crucial prognostic signaling pathways of pancreatic ductal adenocarcinoma were identified by single-cell and bulk RNA sequencing data.Human genetics · 2024Article
- Construction and validation of a pancreatic cancer prognostic model based on genes related to the hypoxic tumor microenvironment.World journal of gastroenterology · 2024Article
- Alterations in genes involved in glycolysis and hypoxia affect the prognosis of pancreatic cancer.Heliyon · 2024Article
- A Novel Pancreatic Cancer Hypoxia Status Related Gene Signature for Prognosis and Therapeutic Responses.Molecular biotechnology · 2024Review
- Progress of single-cell RNA sequencing combined with spatial transcriptomics in tumour microenvironment and treatment of pancreatic cancer.Journal of translational medicine · 2024Review
- Establishment of a circRNA-regulated E3 ubiquitin ligase signature and nomogram to predict immunotherapeutic efficacy and prognosis in hepatocellular carcinoma.European journal of medical research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aim to construct a hypoxia- and immune-associated risk score model to predict the prognosis of patients with pancreatic ductal adenocarcinoma (PDAC). By unsupervised consensus clustering algorithms, we generate two different hypoxia clusters. Then, we screened out 682 hypoxia-associated and 528 immune-associated PDAC differentially expressed genes (DEGs) of PDAC using Pearson correlation analysis based on the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression project (GTEx) dataset. Seven hypoxia and immune-associated signature genes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.